Literature DB >> 12585907

Efficient synthesis of enantiomerically pure beta2-amino acids via chiral isoxazolidinones.

Hee-Seung Lee1, Jin-Seong Park, Byeong Moon Kim, Samuel H Gellman.   

Abstract

We report a practical and scalable synthetic route for the preparation of alpha-substituted beta-amino acids (beta(2)-amino acids). Michael addition of a chiral hydroxylamine, derived from alpha-methylbenzylamine, to an alpha-alkylacrylate followed by cyclization gives a diastereomeric mixture of alpha-substituted isoxazolidinones. These diastereomers are separable by column chromatography. Subsequent hydrogenation of the purified isoxazolidinones followed by Fmoc protection affords enantiomerically pure Fmoc-beta(2)-amino acids, which are useful for beta-peptide synthesis. This route provides access to both enantiomers of a protected beta(2)-amino acid.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12585907     DOI: 10.1021/jo026738b

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  10 in total

1.  Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.

Authors:  Janelle Lauer-Fields; Keith Brew; John K Whitehead; Shunzi Li; Robert P Hammer; Gregg B Fields
Journal:  J Am Chem Soc       Date:  2007-08-02       Impact factor: 15.419

2.  Direct Access to Versatile Electrophiles via Catalytic Oxidative Cyanation of Alkenes.

Authors:  De-Wei Gao; Ekaterina V Vinogradova; Sri Krishna Nimmagadda; Jose M Medina; Yiyang Xiao; Radu M Suciu; Benjamin F Cravatt; Keary M Engle
Journal:  J Am Chem Soc       Date:  2018-06-22       Impact factor: 15.419

3.  Synthesis, pharmacological evaluation and conformational investigation of endomorphin-2 hybrid analogues.

Authors:  Giordano Lesma; Severo Salvadori; Francesco Airaghi; Engin Bojnik; Anna Borsodi; Teresa Recca; Alessandro Sacchetti; Gianfranco Balboni; Alessandra Silvani
Journal:  Mol Divers       Date:  2012-11-04       Impact factor: 2.943

4.  Enantioselective rhodium enolate protonations. A new methodology for the synthesis of beta2-amino acids.

Authors:  Mukund P Sibi; Hiroto Tatamidani; Kalyani Patil
Journal:  Org Lett       Date:  2005-06-23       Impact factor: 6.005

5.  Structural and biological exploration of phe(3)-phe(4)-modified endomorphin-2 peptidomimetics.

Authors:  Giordano Lesma; Severo Salvadori; Francesco Airaghi; Thomas F Murray; Teresa Recca; Alessandro Sacchetti; Gianfranco Balboni; Alessandra Silvani
Journal:  ACS Med Chem Lett       Date:  2013-07-11       Impact factor: 4.345

6.  Efficient synthesis of Fmoc-protected phosphinic pseudodipeptides: Building blocks for the synthesis of matrix metalloproteinase inhibitors.

Authors:  Manishabrata Bhowmick; Ravinder R Sappidi; Gregg B Fields; Salvatore D Lepore
Journal:  Biopolymers       Date:  2011       Impact factor: 2.505

7.  Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB.

Authors:  Marco Pieroni; Suresh K Tipparaju; Shichun Lun; Yang Song; A Willem Sturm; William R Bishai; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2011-01-21       Impact factor: 3.466

8.  Synthesis of Fmoc-Gly-Ile Phosphinic Pseudodipeptide: Residue Specific Conditions for Construction of Matrix Metalloproteinase Inhibitor Building Blocks.

Authors:  Manishabrata Bhowmick; Gregg B Fields
Journal:  Int J Pept Res Ther       Date:  2012-12       Impact factor: 1.931

9.  Direct amination of homoenolates catalyzed by N-heterocyclic carbenes.

Authors:  Audrey Chan; Karl A Scheidt
Journal:  J Am Chem Soc       Date:  2008-02-09       Impact factor: 15.419

10.  Iterative in situ click chemistry creates antibody-like protein-capture agents.

Authors:  Heather D Agnew; Rosemary D Rohde; Steven W Millward; Arundhati Nag; Woon-Seok Yeo; Jason E Hein; Suresh M Pitram; Abdul Ahad Tariq; Vanessa M Burns; Russell J Krom; Valery V Fokin; K Barry Sharpless; James R Heath
Journal:  Angew Chem Int Ed Engl       Date:  2009       Impact factor: 15.336

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.